CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder

Here we report 3 cases of neuromyelitis optica spectrum disorder (NMOSD), who were all treated with eculizumab and could be observed with monitoring serum C3, C4 and 50% hemolytic complement (CH50) before and after the treatment. Serum C3 and C4 were not dramatically changed during the treatment, in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Heliyon
Autors principals: Namatame, Chihiro, Misu, Tatsuro, Takai, Yoshiki, Nishiyama, Shuhei, Nakashima, Ichiro, Fujihara, Kazuo, Aoki, Masashi
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7809378/
https://ncbi.nlm.nih.gov/pubmed/33490671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.heliyon.2021.e05899
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars